Armata Pharmaceuticals Inc (ARMP)
2.36
+0.07
(+3.06%)
USD |
NYAM |
Sep 27, 16:00
Armata Pharmaceuticals SG&A Expense (Annual): 11.65M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.65M |
| December 31, 2022 | 7.437M |
| December 31, 2021 | 8.281M |
| December 31, 2020 | 7.966M |
| December 31, 2019 | 9.265M |
| December 31, 2018 | 5.702M |
| December 31, 2017 | 7.59M |
| December 31, 2016 | 8.413M |
| December 31, 2015 | 6.71M |
| December 31, 2014 | 6.85M |
| December 31, 2013 | 5.996M |
| December 31, 2012 | 3.208M |
| December 31, 2008 | 5.822M |
| December 31, 2007 | 7.029M |
| Date | Value |
|---|---|
| December 31, 2006 | 6.382M |
| December 31, 2005 | 6.313M |
| December 31, 2004 | 6.65M |
| December 31, 2003 | 5.49M |
| December 31, 2002 | 8.067M |
| December 31, 2001 | 8.531M |
| December 31, 2000 | 7.531M |
| December 31, 1999 | 3.60M |
| December 31, 1998 | 3.00M |
| December 31, 1997 | 2.80M |
| December 31, 1996 | 2.90M |
| December 31, 1995 | 2.30M |
| December 31, 1994 | 1.90M |
| December 31, 1993 | 5.50M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.437M
Minimum
2022
11.65M
Maximum
2023
8.920M
Average
8.281M
Median
2021
SG&A Expense (Annual) Benchmarks
| AIM ImmunoTech Inc | 21.14M |
| Perspective Therapeutics Inc | 21.06M |
| Protalix BioTherapeutics Inc | 14.96M |
| Electromed Inc | 34.49M |
| Xtant Medical Holdings Inc | 64.29M |